The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Amphiregulin (AREG) SNP rs161511 to predict cetuximab efficacy independent of AREG mRNA levels: Data from FIRE3 (AIO KRK-0306).
Sebastian Stintzing
Consultant or Advisory Role - Bristol-Myers Squibb; Merck KGaA; Roche/Genentech
Honoraria - Amgen; Merck KGaA; Roche/Genentech; Sanofi ; Sirtex Medical
Stefan Stremitzer
No relevant relationships to disclose
Volker Heinemann
Consultant or Advisory Role - Amgen; Bayer; Merck KGaA; Roche/Genentech; Sanofi
Honoraria - Amgen; Bayer; Merck KGaA; Roche/Genentech; Sanofi
Research Funding - Amgen; Merck Serono; Roche/Genentech
Andreas Jung
Consultant or Advisory Role - Amgen; Merck Serono
Honoraria - Amgen; Merck Serono
Yu Sunakawa
No relevant relationships to disclose
Satoshi Matsusaka
No relevant relationships to disclose
Shinichi Yamauchi
No relevant relationships to disclose
Wu Zhang
No relevant relationships to disclose
Dongyun Yang
No relevant relationships to disclose
Yan Ning
No relevant relationships to disclose
Ana Sebio
No relevant relationships to disclose
Diana L. Hanna
No relevant relationships to disclose
Saadat Siamak
No relevant relationships to disclose
Heinz-Josef Lenz
No relevant relationships to disclose